Loading...
XOSL
GENT
Market cap73mUSD
May 05, Last price  
49.40NOK
1D
-1.00%
1Q
12.27%
Jan 2017
-6.79%
IPO
76.43%
Name

Gentian Diagnostics ASA

Chart & Performance

D1W1MN
XOSL:GENT chart
No data to show
P/E
16.82
P/S
5.01
EPS
2.94
Div Yield, %
—
Shrs. gr., 5y
0.76%
Rev. gr., 5y
25.96%
Revenues
152m
+11.66%
22,893,74224,554,41625,586,95430,896,88734,988,95946,108,22047,952,00068,369,00083,122,000101,636,000136,193,000152,070,000
Net income
45m
P
873,987-2,908,559-3,222,155-8,926,987-15,169,906-19,798,354-39,857,000-17,114,000-24,794,000-24,001,000-10,648,00045,293,000
CFO
13m
-12.94%
2,433,754-1,950,715-4,626,008-7,901,630-18,632,886-10,896,653-21,483,000-7,661,000-27,053,000-13,952,00015,458,00013,457,000

Profile

Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, and the United States. It offers in-vitro diagnostic reagents for clinical chemistry analyzers. The company's products include the gentian calprotectin immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; NT-proBNP Immunoassay for diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure; and Canine c-reactive protein (CRP) immunoassay, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine CRP in dog plasma and serum. It also provides turbidimetric SARS-CoV-2 total antibody immunoassay, a quantitative antibody test for detecting antibodies targeting the S1-subunit. The company was incorporated in 2001 and is headquartered in Moss, Norway.
URL
https://www.gentian.com/
IPO date
Dec 14, 2016
Employees
55
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
152,070
11.66%
136,193
34.00%
101,636
22.27%
Cost of revenue
140,948
68,852
79,716
Unusual Expense (Income)
NOPBT
11,122
67,341
21,920
NOPBT Margin
7.31%
49.45%
21.57%
Operating Taxes
(25,229)
282
383
Tax Rate
0.42%
1.75%
NOPAT
36,351
67,059
21,537
Net income
45,293
-525.37%
(10,648)
-55.64%
(24,001)
-3.20%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
4,043
3,699
Long-term debt
11,014
22,055
26,947
Deferred revenue
Other long-term liabilities
(1,000)
Net debt
(73,724)
(61,645)
(50,953)
Cash flow
Cash from operating activities
13,457
15,458
(13,952)
CAPEX
(1,377)
(955)
(14,666)
Cash from investing activities
(10,950)
(4,877)
(14,666)
Cash from financing activities
(4,950)
(4,598)
(4,325)
FCF
30,646
72,705
13,872
Balance
Cash
84,738
87,642
81,599
Long term investments
101
Excess cash
77,134
80,933
76,517
Stockholders' equity
(120,668)
(165,507)
(154,935)
Invested Capital
320,224
325,192
319,463
ROIC
11.26%
20.80%
6.86%
ROCE
5.57%
42.15%
13.32%
EV
Common stock shares outstanding
15,997
15,422
15,422
Price
39.20
-5.54%
41.50
1.22%
41.00
-43.06%
Market cap
627,094
-2.02%
640,013
1.22%
632,302
-43.03%
EV
553,370
578,368
581,860
EBITDA
20,085
76,907
32,163
EV/EBITDA
27.55
7.52
18.09
Interest
2,516
871
1,255
Interest/NOPBT
22.62%
1.29%
5.73%